Physician profile
Vera Saprounova
NPI 1033193305
$947.60
in general payments reported to CMS, 2019-2025
21 companies · $47.33 in 2025
The $47.33 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $111 · 2021: $119 · 2022: $73.58 · 2023: $111 · 2024: $110 · 2025: $47.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $252 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $251.65 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $231.99 | 2019-2021 | |
| Abbvie INC. | $132.64 | 2021-2024 | Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $91.10 | 2020-2024 | Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.87 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $49.20 | 2022-2023 | |
| Exact Sciences Corporation | $45.96 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $33.39 | 2019 | |
| Allergan, INC. | $29.39 | 2020 | |
| Alnylam Pharmaceuticals INC. | $23.71 | 2025 | Onpattro |
| Novartis Pharmaceuticals Corporation | $22.53 | 2019 | |
| Pfizer INC. | $22.29 | 2019 | |
| Acadia Pharmaceuticals INC | $20.77 | 2019 | |
| Neurelis, INC. | $20.74 | 2022 | |
| Merck Sharp & Dohme LLC | $20.72 | 2023 | Dificid, Pifeltro, Delstrigo |
| Teva Pharmaceuticals USA, INC. | $20.03 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $17.94 | 2019 | |
| Aimmune Therapeutics, INC. | $17.17 | 2023 | |
| Stimwave Technologies Incorporated | $16.14 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.01 | 2021 | |
| Glaxosmithkline, LLC. | $15.75 | 2024 | Trelegy Ellipta |
| Lundbeck LLC | $15.26 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vera Saprounova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.